Curated News
By: NewsRamp Editorial Staff
November 10, 2026
Lantern Pharma Publishes Phase 1a Data for LP-184 in Recurrent GBM
TLDR
- Lantern Pharma's LP-184 plus spironolactone strategy, backed by FDA Fast Track and AI-driven RADR, targets first GBM recurrence with a planned Phase 1b/2a trial.
- LP-184 was well tolerated at 0.39 mg/kg in 16 recurrent GBM patients, and adding spironolactone cut the effective dose threefold to sixfold preclinically.
- Lantern Pharma's study offers hope for recurrent glioblastoma patients by repurposing spironolactone to potentially improve LP-184 efficacy and extend stable disease.
- One recurrent glioblastoma patient remained clinically and radiographically stable for over 22 months after LP-184 enrollment, despite no objective radiographic responses.
Impact - Why it Matters
The publication of these Phase 1a data is a critical milestone for Lantern Pharma and Starlight Therapeutics, as it provides a clear dosing rationale and safety profile for LP-184 in recurrent glioblastoma, a devastating disease with limited treatment options. The finding that one patient remained stable for over 22 months, despite no objective responses, hints at potential clinical benefit and supports the planned Phase 1b/2a trial combining LP-184 with spironolactone. This combination strategy, bolstered by Lantern’s RADR AI platform, could enhance drug exposure in brain tumors and improve efficacy. For patients with recurrent GBM, who face a median survival of less than a year, this news offers a glimmer of hope and a potential new therapeutic avenue. For investors, it validates Lantern’s AI-driven approach and underscores the company’s commitment to advancing precision oncology, potentially leading to value creation if the combination proves successful in later trials.
Summary
Lantern Pharma (NASDAQ: LTRN) and its wholly owned subsidiary, Starlight Therapeutics, have published Phase 1a clinical data for LP-184 (zirdafulven), also known as STAR-001, in patients with recurrent glioblastoma (GBM). The study, featured in the October 2026 issue of Cancer Research Communications, evaluated 16 patients and found that LP-184 was generally well tolerated, with a recommended expansion dose of 0.39 mg/kg established. Although no objective radiographic responses were observed, one patient remained clinically and radiographically stable for more than 22 months after enrollment. The findings also revealed limited drug exposure in brain tumors, supporting further evaluation of LP-184 in combination with spironolactone, an FDA-approved drug that reduced the concentration of LP-184 needed to kill GBM cells by threefold to sixfold in preclinical models.
The company said the findings establish a dosing rationale for a planned Phase 1b/2a trial evaluating LP-184 plus spironolactone in patients experiencing their first GBM recurrence. The study, sponsored by Starlight Therapeutics under an FDA-cleared Investigational New Drug application, will assess safety, pharmacokinetics, and objective response. The combination strategy was developed with support from Lantern’s RADR® AI platform and research collaborators at Johns Hopkins University. LP-184 has received FDA Fast Track Designation for GBM and triple-negative breast cancer, along with Orphan Drug Designations for certain central nervous system cancers. Lantern Pharma is a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence and machine-learning platform to transform the cost, pace, and precision of oncology drug development. To view the full press release, visit https://ibn.fm/qaLVQ.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma Publishes Phase 1a Data for LP-184 in Recurrent GBM
